“This additional production will help us continue to scale up our manufacturing capacity in the United States,” Juan Andres, Moderna’s chief technical operations and quality officer, said in the statement.
Manufacturing will take place in Bloomington, Ind., at Baxter’s BioPharma Solutions, which specializes in injectable pharmaceuticals. There are more than 700 employees at the 600,000-square-foot campus.
Baxter's stock price inched up on the news, increasing 0.4 percent to $78.35 this morning.
The deal follows a similar manufacturing agreement with Gaithersburg, Maryland-based Novavax. In January, Baxter announced it would provide manufacturing services for the drugmaker’s COVID-19 vaccine candidate in international markets.
“The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all,” Marie Keeley, vice president of Baxter BioPharma Solutions, said in a statement at the time.
Moderna has deals with the U.S. government to provide 300 million doses of its vaccine this year. It said in February it aimed to complete delivery of the doses by the end of July, and was looking at ways to accelerate the process.